CoChat

Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis

Deeb, Kristin K., Michalowska, Aleksandra M., Yoon, Cheol-yong, Krummey, Scott M., Hoenerhoff, Mark J., Kavanaugh, Claudine, Li, Ming-chung, Demayo, Francesco J., Linnoila, Ilona, Deng, Chu-xia, Lee, Eva Y-H.P., Medina, Daniel, Shih, Joanna H., Green, Jeffrey E. · 2007 · Cancer Research
Cited by 102

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Understanding the genetic architecture of cancer pathways that distinguishes subsets of human cancer is critical to developing new therapies that better target tumors based on their molecular expression profiles. In this study, we identify an integrated gene signature from multiple transgenic models of epithelial cancers intrinsic to the functions of the Simian virus 40 T/t-antigens that is associated with the biological behavior and prognosis for several human epithelial tumors. This genetic signature, composed primarily of genes regulating cell replication, proliferation, DNA repair, and apoptosis, is not a general cancer signature. Rather, it is uniquely activated primarily in tumors with aberrant p53, Rb, or BRCA1 expression but not in tumors initiated through the overexpression of myc, ras, her2/neu, or polyoma middle T oncogenes. Importantly, human breast, lung, and prostate tumors expressing this set of genes represent subsets of tumors with the most aggressive phenotype and with poor prognosis. The T/t-antigen signature is highly predictive of human breast cancer prognosis. Because this class of epithelial tumors is generally intractable to currently existing standard therapies, this genetic signature identifies potential targets for novel therapies directed against these lethal forms of cancer. Because these genetic targets have been discovered using mammary, prostate, and lung T/t-antigen mouse cancer models, these models are rationale candidates for use in preclinical testing of therapies focused on these biologically important targets. [Cancer Res 2007;67(17):8065–80]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-07-1515

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 102

Metadata

Authors
Deeb, K. K., Michalowska, A. M., Yoon, C.-Y., Krummey, S. M., Hoenerhoff, M. J., Kavanaugh, C., Li, M.-C., Demayo, F. J., Linnoila, I., Deng, C.-X., Lee, E. Y.-H. P., Medina, D., Shih, J. H., & Green, J. E.
Venue
Cancer Research
Published
2007-09-01
Volume
67
Issue
17
Pages
8065-8080
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2144465725
Cited by
102
References
4
FWCI
5.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-1515
The paper
Deeb, K. K., Michalowska, A. M., Yoon, C.-Y., Krummey, S. M., Hoenerhoff, M. J., Kavanaugh, C., Li, M.-C., Demayo, F. J., Linnoila, I., Deng, C.-X., Lee, E. Y.-H. P., Medina, D., Shih, J. H., & Green, J. E. (2007). Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-1515

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.